A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).

NCT05947851 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

735

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia, Chronic Lymphocytic
Small-Cell Lymphoma
Lymphoma, Small Lymphocytic
CLL
SLL

Interventions

DRUG: Nemtabrutinib
DRUG: Venetoclax
BIOLOGICAL: Rituximab

Sponsor

Merck Sharp & Dohme LLC